Pain and Therapy is a prestigious, peer-reviewed journal published by SPRINGER INTERNATIONAL PUBLISHING AG that has been a beacon of research in the field of pain management and neurology since its inception in 2012. With an ISSN of 2193-8237 and an E-ISSN of 2193-651X, this open access journal facilitates the dissemination of high-quality research to a global audience. Recognized within the top Q1 quartile for Anesthesiology and Pain Medicine, and the Q2 category for Clinical Neurology, it ranks impressively within the Scopus indexing, positioned at #20/136 in its primary category, demonstrating an 85th percentile standing. The journal's commitment to open access enhances its impact, allowing researchers, clinicians, and students to explore and contribute to critical developments in pain therapy and management. The convergence of cutting-edge research and innovative therapeutic strategies makes Pain and Therapy an essential resource for anyone dedicated to advancing knowledge in this vital field.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, published by SAGE Publications Ltd, serves as a vital platform in the fields of biochemistry and medicine, showcasing significant research contributions since its inception in 1972. With an Open Access policy implemented in 2012, this journal promotes unrestricted dissemination of knowledge, catering to a global audience and ensuring that critical findings are accessible to researchers, healthcare professionals, and students alike. With an impressive scope spanning diverse biomedical disciplines, the journal ranks in the Q3 quartile for both biochemistry and medicine, affirming its relevance and impact within these evolving fields. Hailing from the United Kingdom, the journal is dedicated to fostering a rich academic dialogue that bridges laboratory discoveries and clinical applications, making it an essential resource for those engaged in international medical research. Its ongoing commitment to excellence is reflected in its convergence until 2024, inviting high-quality submissions that contribute to advancements in medical science.

The New England Journal of Medicine (NEJM), published by the Massachusetts Medical Society, stands as a beacon of excellence in the field of medicine. With an impressive impact factor and a prestigious rank of #2 out of 636 in General Medicine, NEJM is recognized in the Q1 category for its significant contributions to medical research and clinical practice since its inception in 1945. The journal is renowned for publishing groundbreaking studies, reviews, and commentaries that influence clinical guidelines and healthcare policies worldwide. While the journal is not open access, it provides pivotal resources that are essential for researchers, healthcare professionals, and students looking to stay abreast of the latest developments in medicine. With a commitment to advancing medical knowledge, NEJM plays a crucial role in bridging the gap between laboratory research and clinical application.

Clinical Trials, published by SAGE Publications Ltd, is a prestigious journal that serves as a vital resource for researchers, professionals, and students in the fields of medicine and pharmacology. Operating since 2004 and converging through 2024, this journal boasts an impressive standing in the academic community, achieving a Q1 categorization in both Medicine (miscellaneous) and Pharmacology as of 2023. The journal's Scopus rankings reflect its influential contributions, with a rank of #128 out of 636 in General Medicine and a 79th percentile placement, alongside a rank of #172 out of 313 in Pharmacology, indicating its significant role in advancing clinical research. Based in the United Kingdom, Clinical Trials focuses on disseminating high-quality studies that enhance the understanding of clinical processes and therapeutic methodologies. Although it does not currently offer Open Access, the journal provides a platform for traditional publication, ensuring the dissemination of critical knowledge in the healthcare domain.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

VALUE IN HEALTH, published by Elsevier Science Inc, is a premier peer-reviewed journal in the fields of Health Policy, Medicine, and Public Health. With an impressive impact factor reflecting its respected standing, the journal has achieved a distinguished Q1 classification in multiple categories, placing it among the top publications in the health domain. Since its inception in 1998, this journal has been a vital platform for disseminating research that informs health policy and practice, impacting both clinical and public health decision-making. The journal’s Scopus rankings further underscore its global influence, with notable positions in Medicine and Public Health sectors. VALUE IN HEALTH is committed to fostering an environment where innovative research meets practical application, ultimately aiming to enhance health outcomes worldwide. Researchers, professionals, and students alike are encouraged to explore the wealth of knowledge contained within its pages.

The International Journal of Biostatistics, published by Walter de Gruyter GmbH, stands as a critical platform for advancements in the fields of biostatistics and applied statistics in medicine. With an ISSN of 2194-573X and an E-ISSN of 1557-4679, this journal has gained recognition for its rigorous peer-reviewed articles that bridge theoretical statistics and its practical applications in health sciences, maintaining a commendable Q2 quartile ranking in both Medicine and Statistics categories as of 2023. Hosted in Germany, the journal's pivotal role lies in disseminating innovative research findings that guide public health decisions and inform healthcare policy, thus appealing to a diverse readership including researchers, healthcare professionals, and students. Although the journal operates under a subscription model, it remains committed to providing valuable insights into the statistical methods that support evidence-based medicine and improve health outcomes globally. For those engaged in the evolving landscape of biostatistics, the International Journal of Biostatistics serves as an indispensable resource through its comprehensive coverage from 2005 to 2024.

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

Trials, published by BMC, is a leading open access journal that has been pioneering advancements in the field of medicine and pharmacology since its inception in 2006. With an impressive E-ISSN of 1745-6215, the journal is based in the United Kingdom and operates from its address at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND. Trials is recognized for its impactful contributions to the research community, achieving a Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories according to the 2023 category quartiles. This esteemed journal aims to provide a platform for presenting cutting-edge clinical trials and methodological advances, effectively fostering collaboration and innovation among researchers, professionals, and students. The journal's accessibility, supported by its open access model, enhances the visibility and dissemination of vital research findings, ensuring that every contribution reaches a broad audience. As of 2024, Trials continues to be a crucial resource for anyone passionate about exploring new frontiers in medical research.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.